Do analysts rate HOOK or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score HOOKIPA Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, HOOK or UPC?

Universe Pharmaceuticals has higher revenue and earnings than HOOKIPA Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HOOKIPA Pharma $9.35M 1.52 -$43.50M -$3.54 N/A Universe Pharmaceuticals $17.86M 0.14 -$3.67M N/A N/A

Do analysts prefer GRTX or UPC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, GRTX or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Galera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galera Therapeutics N/A N/A -$59.08M $0.64 0.14 Universe Pharmaceuticals $17.86M 0.14 -$3.67M N/A N/A

Is GRTX or UPC more profitable?

Company Net Margins Return on Equity Return on Assets Galera Therapeutics N/A N/A -99.34% Universe Pharmaceuticals N/A N/A N/A

Do analysts recommend MBRX or UPC?

Moleculin Biotech presently has a consensus target price of $22.00, suggesting a potential upside of 873.45%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, MBRX or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Moleculin Biotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moleculin Biotech N/A N/A -$33.56M -$17.98 N/A Universe Pharmaceuticals $17.86M 0.14 -$3.67M N/A N/A

Is MBRX or UPC more profitable?

Company Net Margins Return on Equity Return on Assets Moleculin Biotech N/A N/A -70.93% Universe Pharmaceuticals N/A N/A N/A

Do analysts prefer INAB or UPC?

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, equities analysts clearly believe IN8bio is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IN8bio 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, INAB or UPC?

Universe Pharmaceuticals has higher revenue and earnings than IN8bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IN8bio N/A N/A -$19.44M -$2.61 N/A Universe Pharmaceuticals $17.86M 0.14 -$3.67M N/A N/A

Is INAB or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat IN8bio's return on equity. Company Net Margins Return on Equity Return on Assets IN8bio N/A -96.39% -80.18% Universe Pharmaceuticals N/A N/A N/A

Do analysts prefer LEXX or UPC?

Lexaria Bioscience presently has a consensus target price of $1.50, suggesting a potential upside of 155.45%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Lexaria Bioscience is more favorable than Universe Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexaria Bioscience 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Universe Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings & valuation, LEXX or UPC?

Universe Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexaria Bioscience $710K 20.50 -$11.90M -$0.47 N/A Universe Pharmaceuticals $17.86M 0.14 -$3.67M N/A N/A

Is LEXX or UPC more profitable?

Universe Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -173.93% -138.79% Universe Pharmaceuticals N/A N/A N/A

Universe Pharmaceuticals (UPC) Competitors

$4.62 +0.17 (+3.82%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$4.48 -0.14 (-3.12%)

As of 07/14/2026 07:52 PM Eastern

Compare

UPC vs. HOOK, GRTX, MBRX, INAB, and LEXX

Should you buy Universe Pharmaceuticals stock or one of its competitors? MarketBeat compares Universe Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Universe Pharmaceuticals include HOOKIPA Pharma (HOOK), Galera Therapeutics (GRTX), Moleculin Biotech (MBRX), IN8bio (INAB), and Lexaria Bioscience (LEXX). These companies are all part of the "pharmaceutical products" industry.

How does Universe Pharmaceuticals compare to HOOKIPA Pharma?

HOOKIPA Pharma (NASDAQ:HOOK) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment and valuation.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than HOOKIPA Pharma. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for HOOKIPA Pharma. Universe Pharmaceuticals' average media sentiment score of 0.44 beat HOOKIPA Pharma's score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
HOOKIPA Pharma	Neutral
Universe Pharmaceuticals	Neutral

63.9% of HOOKIPA Pharma shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 3.3% of HOOKIPA Pharma shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

HOOKIPA Pharma has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HOOKIPA Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has a net margin of 0.00% compared to HOOKIPA Pharma's net margin of -785.66%. Universe Pharmaceuticals' return on equity of 0.00% beat HOOKIPA Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HOOKIPA Pharma	-785.66%	-120.09%	-77.14%
Universe Pharmaceuticals	N/A	N/A	N/A

Universe Pharmaceuticals has higher revenue and earnings than HOOKIPA Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HOOKIPA Pharma	$9.35M	1.52	-$43.50M	-$3.54	N/A
Universe Pharmaceuticals	$17.86M	0.14	-$3.67M	N/A	N/A

Summary

Universe Pharmaceuticals beats HOOKIPA Pharma on 10 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Galera Therapeutics?

Galera Therapeutics (NASDAQ:GRTX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, media sentiment, earnings, analyst recommendations, profitability and risk.

In the previous week, Universe Pharmaceuticals had 2 more articles in the media than Galera Therapeutics. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 0 mentions for Galera Therapeutics. Universe Pharmaceuticals' average media sentiment score of 0.44 beat Galera Therapeutics' score of 0.00 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Galera Therapeutics	Neutral
Universe Pharmaceuticals	Neutral

Galera Therapeutics has a beta of 2.6, suggesting that its share price is 160% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galera Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Universe Pharmaceuticals has higher revenue and earnings than Galera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galera Therapeutics	N/A	N/A	-$59.08M	$0.64	0.14
Universe Pharmaceuticals	$17.86M	0.14	-$3.67M	N/A	N/A

50.8% of Galera Therapeutics shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 12.9% of Galera Therapeutics shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
Galera Therapeutics	N/A	N/A	-99.34%
Universe Pharmaceuticals	N/A	N/A	N/A

Summary

Universe Pharmaceuticals beats Galera Therapeutics on 7 of the 9 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Moleculin Biotech?

Moleculin Biotech (NASDAQ:MBRX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, risk, media sentiment, analyst recommendations and valuation.

Company	Net Margins	Return on Equity	Return on Assets
Moleculin Biotech	N/A	N/A	-70.93%
Universe Pharmaceuticals	N/A	N/A	N/A

Moleculin Biotech presently has a consensus target price of $22.00, suggesting a potential upside of 873.45%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Moleculin Biotech is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moleculin Biotech	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Universe Pharmaceuticals had 1 more articles in the media than Moleculin Biotech. MarketBeat recorded 2 mentions for Universe Pharmaceuticals and 1 mentions for Moleculin Biotech. Moleculin Biotech's average media sentiment score of 1.89 beat Universe Pharmaceuticals' score of 0.44 indicating that Moleculin Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Moleculin Biotech	Very Positive
Universe Pharmaceuticals	Neutral

Moleculin Biotech has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.46, indicating that its stock price is 46% more volatile than the broader market.

Universe Pharmaceuticals has higher revenue and earnings than Moleculin Biotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moleculin Biotech	N/A	N/A	-$33.56M	-$17.98	N/A
Universe Pharmaceuticals	$17.86M	0.14	-$3.67M	N/A	N/A

15.5% of Moleculin Biotech shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 1.1% of Moleculin Biotech shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Moleculin Biotech beats Universe Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to IN8bio?

IN8bio (NASDAQ:INAB) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, media sentiment, risk, analyst recommendations, institutional ownership and dividends.

Universe Pharmaceuticals has higher revenue and earnings than IN8bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$19.44M	-$2.61	N/A
Universe Pharmaceuticals	$17.86M	0.14	-$3.67M	N/A	N/A

IN8bio currently has a consensus price target of $4.00, suggesting a potential upside of 189.86%. Given IN8bio's stronger consensus rating and higher possible upside, equities analysts clearly believe IN8bio is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

IN8bio has a beta of 0.22, meaning that its stock price is 78% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market.

92.1% of IN8bio shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 14.5% of IN8bio shares are held by insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Universe Pharmaceuticals' return on equity of 0.00% beat IN8bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-96.39%	-80.18%
Universe Pharmaceuticals	N/A	N/A	N/A

In the previous week, IN8bio had 1 more articles in the media than Universe Pharmaceuticals. MarketBeat recorded 3 mentions for IN8bio and 2 mentions for Universe Pharmaceuticals. IN8bio's average media sentiment score of 0.76 beat Universe Pharmaceuticals' score of 0.44 indicating that IN8bio is being referred to more favorably in the media.

Company	Overall Sentiment
IN8bio	Positive
Universe Pharmaceuticals	Neutral

Summary

IN8bio and Universe Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Universe Pharmaceuticals compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and Universe Pharmaceuticals (NASDAQ:UPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

Universe Pharmaceuticals has higher revenue and earnings than Lexaria Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	20.50	-$11.90M	-$0.47	N/A
Universe Pharmaceuticals	$17.86M	0.14	-$3.67M	N/A	N/A

Universe Pharmaceuticals' return on equity of 0.00% beat Lexaria Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-173.93%	-138.79%
Universe Pharmaceuticals	N/A	N/A	N/A

In the previous week, Lexaria Bioscience and Lexaria Bioscience both had 2 articles in the media. Universe Pharmaceuticals' average media sentiment score of 0.44 beat Lexaria Bioscience's score of -0.57 indicating that Universe Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Lexaria Bioscience	Negative
Universe Pharmaceuticals	Neutral

Lexaria Bioscience presently has a consensus target price of $1.50, suggesting a potential upside of 155.45%. Given Lexaria Bioscience's stronger consensus rating and higher probable upside, equities analysts clearly believe Lexaria Bioscience is more favorable than Universe Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Universe Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lexaria Bioscience has a beta of 0.34, meaning that its share price is 66% less volatile than the broader market. Comparatively, Universe Pharmaceuticals has a beta of 1.46, meaning that its share price is 46% more volatile than the broader market.

13.1% of Lexaria Bioscience shares are held by institutional investors. Comparatively, 0.2% of Universe Pharmaceuticals shares are held by institutional investors. 8.4% of Lexaria Bioscience shares are held by company insiders. Comparatively, 57.4% of Universe Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Universe Pharmaceuticals beats Lexaria Bioscience on 7 of the 12 factors compared between the two stocks.

Get Universe Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

UPC vs. The Competition

Export

Metric	Universe Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.51M	$3.02B	$6.86B	$12.44B
Dividend Yield	N/A	2.08%	2.68%	8.42%
P/E Ratio	N/A	18.77	27.01	24.38
Price / Sales	0.14	344.35	522.34	91.89
Price / Cash	N/A	56.83	48.59	59.36
Price / Book	0.05	4.20	10.80	6.33
Net Income	-$3.67M	$65.13M	$3.59B	$331.02M
7 Day Performance	-20.34%	-2.63%	-1.49%	-0.33%
1 Month Performance	48.08%	2.14%	2.79%	-1.29%
1 Year Performance	24.19%	23.26%	28.56%	21.30%

Universe Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
UPC Universe Pharmaceuticals	0.4157 of 5 stars	$4.62 +3.8%	N/A	+20.6%	$2.51M	$17.86M	N/A	220
HOOK HOOKIPA Pharma	N/A	$1.15 flat	N/A	-4.2%	$14.18M	$9.35M	N/A	160	Gap Down
GRTX Galera Therapeutics	N/A	$0.09 -3.7%	N/A	+238.5%	$14.13M	N/A	N/A	30
MBRX Moleculin Biotech	2.9029 of 5 stars	$2.40 -9.1%	$22.00 +816.7%	-85.7%	$14.09M	N/A	N/A	20	Positive News
INAB IN8bio	3.9306 of 5 stars	$1.44 +1.4%	$4.00 +177.8%	-37.8%	$13.98M	N/A	N/A	20

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:UPC) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Universe Pharmaceuticals (UPC) Competitors

UPC vs. HOOK, GRTX, MBRX, INAB, and LEXX

How does Universe Pharmaceuticals compare to HOOKIPA Pharma?

Summary

How does Universe Pharmaceuticals compare to Galera Therapeutics?

Summary

How does Universe Pharmaceuticals compare to Moleculin Biotech?

Summary

How does Universe Pharmaceuticals compare to IN8bio?

Summary

How does Universe Pharmaceuticals compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Universe Pharmaceuticals (UPC) Competitors

UPC vs. HOOK, GRTX, MBRX, INAB, and LEXX

How does Universe Pharmaceuticals compare to HOOKIPA Pharma?

Does the media favor HOOK or UPC?

Do insiders and institutionals believe in HOOK or UPC?

Which has more risk and volatility, HOOK or UPC?

Do analysts rate HOOK or UPC?

Is HOOK or UPC more profitable?

Which has preferable valuation and earnings, HOOK or UPC?

Summary

How does Universe Pharmaceuticals compare to Galera Therapeutics?

Does the media favor GRTX or UPC?

Which has more risk and volatility, GRTX or UPC?

Do analysts prefer GRTX or UPC?

Which has stronger valuation & earnings, GRTX or UPC?

Do insiders & institutionals have more ownership in GRTX or UPC?

Is GRTX or UPC more profitable?

Summary

How does Universe Pharmaceuticals compare to Moleculin Biotech?

Is MBRX or UPC more profitable?

Do analysts recommend MBRX or UPC?

Does the media favor MBRX or UPC?

Which has more risk and volatility, MBRX or UPC?

Which has stronger valuation and earnings, MBRX or UPC?

Do institutionals & insiders have more ownership in MBRX or UPC?

Summary

How does Universe Pharmaceuticals compare to IN8bio?

Which has better valuation and earnings, INAB or UPC?

Do analysts prefer INAB or UPC?

Which has more risk and volatility, INAB or UPC?

Do institutionals & insiders hold more shares of INAB or UPC?

Is INAB or UPC more profitable?

Does the media prefer INAB or UPC?

Summary

How does Universe Pharmaceuticals compare to Lexaria Bioscience?

Which has higher earnings & valuation, LEXX or UPC?

Is LEXX or UPC more profitable?

Does the media prefer LEXX or UPC?

Do analysts prefer LEXX or UPC?

Which has more volatility and risk, LEXX or UPC?

Do institutionals and insiders hold more shares of LEXX or UPC?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

UPC vs. The Competition

Universe Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools